CompletedNot Applicable

Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without TACE for Advanced HCC With Vascular Invasions

China2,651 participantsStarted 2018-06-01

Plain-language summary

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma with vascular invasions

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Cholangiocarcinoma, fibrolamellar, sarcomatoid hepatocellular carcinoma, and mixed hepatocellular/cholangiocarcinoma subtypes(confirmed by histology, or pathology) are not eligible;
✕. Unable to meet criteria of combination timeframe described above;
✕. Child-Pugh C or PS\>2 or Severe hepatic encephalopathy

What they're measuring

Overall Survival(OS)

Timeframe: up to approximately 2 years

Progression free survival(PFS) according to per mRECIST or RECIST 1.1

Timeframe: up to approximately 2 years

Trial details

NCT IDNCT06881446

SponsorZhongda Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-03-30

View on ClinicalTrials.gov More Hepatocellular Carcinoma (HCC) trials